---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006668"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:19:51.763766+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celldex Q3 net loss $38.3M ($0.81/shr); Phase 2 CSU enrollment complete, data by YE 2023

## Summary
- Net loss of $38.3M ($0.81 per share) vs $26.8M ($0.57) a year ago; revenue $1.5M.
- Cash, equivalents and marketable securities $235.3M, sufficient to fund operations through 2025.
- Phase 2 CSU study (n=208) enrollment complete; topline data expected by end of 2023.
- Phase 1b prurigo nodularis data accepted for oral presentation at World Congress on Itch (Nov 5-7).
- Phase 2 studies in CIndU, EoE ongoing; Phase 2 PN study planned for early 2024.

## SEC filing metadata
- accession: 0001171843-23-006668
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/0001171843-23-006668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/f8k_110223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006668
- JSON: https://secwatch.observer/filing/0001171843-23-006668.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006668.txt

## Key facts
- Earnings Releases
  Celldex Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $1.5 million.
  - Period: third quarter ended September 30, 2023
  - Revenue: $1.5 million
  - Result: reported results
  source text: activities of $19.0 million for the three months ended September 30, 2023. At September 30, 2023, Celldex had 47.3 million shares outstanding. Revenues: Total revenue was $1.5 million in the third quarter of 2023 and $2.8 million for the nine months ended September 30, 2023, compared to $0.4 million and $0.7 million for the comparable periods in 2022. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/0001171843-23-006668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.